Primmune Therapeutics, Inc.

Carlsbad, CA

UEI
RCE3KW671H83
CAGE
8J8L4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1929 E Pointe Ave, Carlsbad, CA 92008, USA
Website
primmunerx.com
Founded
2017
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $662,794
FY2025 $2,782,285
FY2024 $7,845,610

Top agencies by obligations

Rank Agency Obligated, FY2026–FY2027 Share
1 Defense Threat Reduction Agency $662,794

Contract awards

Award Agency Obligated Awarded
Oral broad spectrum antiviral TLR7 agonist for treatment of lassa fever HDTRA124C0014 Defense Threat Reduction Agency $11,290,689

Quick answers

Is Primmune Therapeutics, Inc. registered in SAM.gov?

Yes. Primmune Therapeutics, Inc.'s SAM.gov registration is active through June 15, 2027.

What is Primmune Therapeutics, Inc.'s CAGE code?

Primmune Therapeutics, Inc.'s CAGE code is 8J8L4, and its Unique Entity ID (UEI) is RCE3KW671H83.

How much has Primmune Therapeutics, Inc. received in federal contracts?

Federal contracts obligated $2,782,285 to Primmune Therapeutics, Inc. in fiscal year 2025 and $11,290,689 in fiscal years 2023 through 2027.

How does Primmune Therapeutics, Inc. rank among federal contractors?

Primmune Therapeutics, Inc. ranked #53 at the Defense Threat Reduction Agency in FY2025.

What is Primmune Therapeutics, Inc.'s most recent federal award?

Primmune Therapeutics, Inc.'s most recent federal contract award is Oral broad spectrum antiviral TLR7 agonist for treatment of lassa fever (HDTRA124C0014), from Defense Threat Reduction Agency, on January 30, 2024.

On GovTribe

See Primmune Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe